Resources
Search all resources on this page or select a tab to see publications, videos, audio, collections of related resources and more.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Information for patients
Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.
Life Saving Drugs Program resources – Perinatal- and infantile-onset hypophosphatasia (HPP)
A collection of resources for health professionals to help people with perinatal- and infantile-onset hypophosphatasia (HPP) access asfotase alfa (Strensiq®) under the Life Saving Drugs Program.
Professor Michael Kidd, Deputy Chief Medical Officer, discusses making healthy choices, and the small steps we can take every day to enjoy a healthy life.
Part of a collection: We answer your top 3 questionsNational Site of Recognition Steering Committee – Meeting 3 – 20 January 2022 – Communique
This communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria
A collection of resources for health professionals to help people with paroxysmal nocturnal haemoglobinuria access eculizumab (Soliris®) under the Life Saving Drugs Program.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
HCAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesThalidomide health practitioner evidence form
This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the HCAF fact sheet
This factsheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesEAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).
Part of a collection: Australian Thalidomide Survivors Support Program resourcesMaking a claim to the EAF fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.
Part of a collection: Australian Thalidomide Survivors Support Program resourcesNational Site of Recognition Steering Committee communique – Meeting 2 – 9 December 2021
Details of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.
Tackling Indigenous Smoking program – Mid-term evaluation report – Executive summary – May 2021
This executive summary of the TIS mid term evaluation report, completed in May 2021, summarises the interim findings from the independent evaluation of the TIS program 2018–19 to 2021–22.
Tackling Indigenous Smoking program – Mid-term evaluation report – December 2020
This mid-term evaluation report, completed in December 2020, presents the interim findings from the independent evaluation of the short and medium-term outcome objectives for the TIS program 2018–19 to 2021–22.
Tackling Indigenous Smoking program – Final evaluation report – July 2018
This report, completed in July 2018, evaluates how effective the Tackling Indigenous Smoking (TIS) program has been and whether it’s on target to achieve its long-term goals.
National Cancer Screening Register – addendum to privacy impact assessment
This report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.
Life Saving Drugs Program – Gaucher disease (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Gaucher diseaseLife Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)Life Saving Drugs Program – Fabry disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Fabry disease.
Part of a collection: Life Saving Drugs Program resources – Fabry diseaseLife Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)Life Saving Drugs Program – Pompe disease – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.
Part of a collection: Life Saving Drugs Program resources – Pompe diseaseLife Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Reapplication
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for paroxysmal nocturnal haemoglobinuria.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria